189 related articles for article (PubMed ID: 25311967)
1. Idarubicin-loaded ONCOZENE drug-eluting embolic agents for chemoembolization of hepatocellular carcinoma: in vitro loading and release and in vivo pharmacokinetics.
Guiu B; Schmitt A; Reinhardt S; Fohlen A; Pohl T; Wendremaire M; Denys A; Blümmel J; Boulin M
J Vasc Interv Radiol; 2015 Feb; 26(2):262-70. PubMed ID: 25311967
[TBL] [Abstract][Full Text] [Related]
2. Idarubicin-Loaded ONCOZENE Drug-Eluting Bead Chemoembolization in a Rabbit Liver Tumor Model: Investigating Safety, Therapeutic Efficacy, and Effects on Tumor Microenvironment.
Borde T; Laage Gaupp F; Geschwind JF; Savic LJ; Miszczuk M; Rexha I; Adam L; Walsh JJ; Huber S; Duncan JS; Peters DC; Sinusas A; Schlachter T; Gebauer B; Hyder F; Coman D; van Breugel JMM; Chapiro J
J Vasc Interv Radiol; 2020 Oct; 31(10):1706-1716.e1. PubMed ID: 32684417
[TBL] [Abstract][Full Text] [Related]
3. Drug-eluting beads loaded with antiangiogenic agents for chemoembolization: in vitro sunitinib loading and release and in vivo pharmacokinetics in an animal model.
Fuchs K; Bize PE; Dormond O; Denys A; Doelker E; Borchard G; Jordan O
J Vasc Interv Radiol; 2014 Mar; 25(3):379-87, 387.e1-2. PubMed ID: 24468044
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of 70-150 μm and 100-300 μm drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma.
Deipolyi AR; Oklu R; Al-Ansari S; Zhu AX; Goyal L; Ganguli S
J Vasc Interv Radiol; 2015 Apr; 26(4):516-22. PubMed ID: 25704226
[TBL] [Abstract][Full Text] [Related]
5. Improved stability of lipiodol-drug emulsion for transarterial chemoembolisation of hepatocellular carcinoma results in improved pharmacokinetic profile: Proof of concept using idarubicin.
Boulin M; Schmitt A; Delhom E; Cercueil JP; Wendremaire M; Imbs DC; Fohlen A; Panaro F; Herrero A; Denys A; Guiu B
Eur Radiol; 2016 Feb; 26(2):601-9. PubMed ID: 26060065
[TBL] [Abstract][Full Text] [Related]
6. Idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma: results of the IDASPHERE phase I trial.
Boulin M; Hillon P; Cercueil JP; Bonnetain F; Dabakuyo S; Minello A; Jouve JL; Lepage C; Bardou M; Wendremaire M; Guerard P; Denys A; Grandvuillemin A; Chauffert B; Bedenne L; Guiu B
Aliment Pharmacol Ther; 2014 Jun; 39(11):1301-13. PubMed ID: 24738629
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Doxorubicin Drug-Eluting Embolic Chemoembolization of Hepatocellular Carcinoma Supplied by Extrahepatic Collateral Arteries.
Lokken RP; Fidelman N; Kolli KP; Kerlan RK
J Vasc Interv Radiol; 2016 Nov; 27(11):1698-1704. PubMed ID: 27397617
[TBL] [Abstract][Full Text] [Related]
8. Idarubicin-loaded Beads for Chemoembolization of Hepatocellular Carcinoma: The IDASPHERE II Single-Arm Phase II Trial.
Guiu B; Chevallier P; Assenat E; Barbier E; Merle P; Bouvier A; Dumortier J; Nguyen-Khac E; Gugenheim J; Rode A; Oberti F; Valette PJ; Yzet T; Chevallier O; Barbare JC; Latournerie M; Boulin M
Radiology; 2019 Jun; 291(3):801-808. PubMed ID: 31038408
[TBL] [Abstract][Full Text] [Related]
9. A Single-Center Retrospective Comparison of Doxorubicin-Loaded HepaSphere Transarterial Chemoembolization with Conventional Transarterial Chemoembolization for Patients with Unresectable Hepatocellular Carcinoma.
Kucukay F; Badem S; Karan A; Ozdemir M; Okten RS; Ozbulbul NI; Kucukay MB; Unlu I; Bostanci EB; Akdogan M
J Vasc Interv Radiol; 2015 Nov; 26(11):1622-9. PubMed ID: 26321015
[TBL] [Abstract][Full Text] [Related]
10. An In Vitro Evaluation of Four Types of Drug-Eluting Embolics Loaded with Idarubicin.
Guiu B; Hincapie G; Thompson L; Wu Y; Boulin M; Cassinotto C; Cruise GM
J Vasc Interv Radiol; 2019 Aug; 30(8):1303-1309. PubMed ID: 31155500
[TBL] [Abstract][Full Text] [Related]
11. Korean Multicenter Registry of Transcatheter Arterial Chemoembolization with Drug-Eluting Embolic Agents for Nodular Hepatocellular Carcinomas: Six-Month Outcome Analysis.
Lee M; Chung JW; Lee KH; Won JY; Chun HJ; Lee HC; Kim JH; Lee IJ; Hur S; Kim HC; Kim YJ; Kim GM; Joo SM; Oh JS
J Vasc Interv Radiol; 2017 Apr; 28(4):502-512. PubMed ID: 27856136
[TBL] [Abstract][Full Text] [Related]
12. Doxorubicin Drug-Eluting Embolic Chemoembolization of Hepatocellular Carcinoma: Study of Midterm Doxorubicin Delivery in Resected Liver Specimens.
D'inca H; Piot O; Diebold MD; Piardi T; Marcus C; Burde F; Sommacale D; Manfait M; Thiéfin G
J Vasc Interv Radiol; 2017 Jun; 28(6):804-810. PubMed ID: 28532743
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Drug-Eluting Embolics versus Conventional Transarterial Chemoembolization for the Treatment of Patients with Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
Wu X; Chapiro J; Malhotra A; Kothary N
J Vasc Interv Radiol; 2021 Jan; 32(1):2-12.e1. PubMed ID: 33160827
[TBL] [Abstract][Full Text] [Related]
14. Transarterial chemoembolization with epirubicin-eluting beads versus transarterial embolization before liver transplantation for hepatocellular carcinoma.
Nicolini A; Martinetti L; Crespi S; Maggioni M; Sangiovanni A
J Vasc Interv Radiol; 2010 Mar; 21(3):327-32. PubMed ID: 20097098
[TBL] [Abstract][Full Text] [Related]
15. Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC.
Prajapati HJ; Xing M; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
AJR Am J Roentgenol; 2014 Dec; 203(6):W706-14. PubMed ID: 25415737
[TBL] [Abstract][Full Text] [Related]
16. DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization.
Lewis AL; Gonzalez MV; Lloyd AW; Hall B; Tang Y; Willis SL; Leppard SW; Wolfenden LC; Palmer RR; Stratford PW
J Vasc Interv Radiol; 2006 Feb; 17(2 Pt 1):335-42. PubMed ID: 16517780
[TBL] [Abstract][Full Text] [Related]
17. Transcatheter arterial chemoembolization with doxorubicin-eluting superabsorbent polymer microspheres in the treatment of hepatocellular carcinoma: midterm follow-up.
Dekervel J; van Malenstein H; Vandecaveye V; Nevens F; van Pelt J; Heye S; Laleman W; Van Steenbergen W; Vaninbroukx J; Verslype C; Maleux G
J Vasc Interv Radiol; 2014 Feb; 25(2):248-55.e1. PubMed ID: 24295569
[TBL] [Abstract][Full Text] [Related]
18. Re: Safety and Efficacy of 70-150 µm and 100-300 µm Drug-Eluting Bead Transarterial Chemoembolization for Hepatocellular Carcinoma.
Tu J; Jia Z; Jiang G
J Vasc Interv Radiol; 2015 Aug; 26(8):1251. PubMed ID: 26210251
[No Abstract] [Full Text] [Related]
19. Transarterial Chemoembolization in a Woodchuck Model of Hepatocellular Carcinoma.
Pritchard WF; Woods DL; Esparza-Trujillo JA; Starost MF; Mauda-Havakuk M; Mikhail AS; Bakhutashvili I; Leonard S; Jones EC; Krishnasamy V; Karanian JW; Wood BJ
J Vasc Interv Radiol; 2020 May; 31(5):812-819.e1. PubMed ID: 32107125
[TBL] [Abstract][Full Text] [Related]
20. Intra-arterial idarubicin_lipiodol without embolisation in hepatocellular carcinoma: The LIDA-B phase I trial.
Guiu B; Jouve JL; Schmitt A; Minello A; Bonnetain F; Cassinotto C; Piron L; Cercueil JP; Loffroy R; Latournerie M; Wendremaire M; Lepage C; Boulin M
J Hepatol; 2018 Jun; 68(6):1163-1171. PubMed ID: 29427728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
